|
Gene: VGLL3 |
Gene summary for VGLL3 |
Gene summary. |
Gene information | Species | Human | Gene symbol | VGLL3 | Gene ID | 389136 |
Gene name | vestigial like family member 3 | |
Gene Alias | VGL-3 | |
Cytomap | 3p12.1 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A8MV65 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
389136 | VGLL3 | ATC11 | Human | Thyroid | ATC | 1.21e-05 | 5.21e-01 | 0.3386 |
389136 | VGLL3 | ATC13 | Human | Thyroid | ATC | 1.07e-15 | 2.76e-01 | 0.34 |
389136 | VGLL3 | ATC2 | Human | Thyroid | ATC | 3.07e-09 | 1.10e+00 | 0.34 |
389136 | VGLL3 | ATC3 | Human | Thyroid | ATC | 1.37e-10 | 6.53e-01 | 0.338 |
389136 | VGLL3 | ATC4 | Human | Thyroid | ATC | 4.13e-02 | 9.87e-02 | 0.34 |
389136 | VGLL3 | ATC5 | Human | Thyroid | ATC | 2.95e-12 | 3.02e-01 | 0.34 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ATC: Anaplastic thyroid cancer | |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
VGLL3 | SNV | Missense_Mutation | novel | c.529G>A | p.Gly177Ser | p.G177S | A8MV65 | protein_coding | tolerated(0.75) | benign(0.018) | TCGA-22-1002-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
VGLL3 | SNV | Missense_Mutation | c.383N>C | p.Gly128Ala | p.G128A | A8MV65 | protein_coding | tolerated(0.28) | possibly_damaging(0.696) | TCGA-63-A5MG-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
VGLL3 | SNV | Missense_Mutation | c.190G>C | p.Glu64Gln | p.E64Q | A8MV65 | protein_coding | tolerated(0.46) | probably_damaging(0.914) | TCGA-66-2794-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
VGLL3 | SNV | Missense_Mutation | novel | c.700N>A | p.Ala234Thr | p.A234T | A8MV65 | protein_coding | tolerated(0.68) | benign(0) | TCGA-77-7141-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
VGLL3 | SNV | Missense_Mutation | novel | c.905T>C | p.Val302Ala | p.V302A | A8MV65 | protein_coding | tolerated(0.19) | possibly_damaging(0.675) | TCGA-77-A5G8-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
VGLL3 | SNV | Missense_Mutation | novel | c.152N>C | p.Met51Thr | p.M51T | A8MV65 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-NC-A5HP-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Chemotherapy | cisplatin | PD |
VGLL3 | deletion | Frame_Shift_Del | c.66delC | p.Met23TrpfsTer23 | p.M23Wfs*23 | A8MV65 | protein_coding | TCGA-05-4432-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | CR | |||
VGLL3 | insertion | Frame_Shift_Ins | novel | c.202_203insT | p.Glu68ValfsTer18 | p.E68Vfs*18 | A8MV65 | protein_coding | TCGA-50-5049-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | ||
VGLL3 | SNV | Missense_Mutation | c.721N>A | p.Arg241Ser | p.R241S | A8MV65 | protein_coding | tolerated(0.34) | benign(0) | TCGA-CV-7415-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
VGLL3 | SNV | Missense_Mutation | novel | c.582N>C | p.Gln194His | p.Q194H | A8MV65 | protein_coding | tolerated(0.12) | possibly_damaging(0.635) | TCGA-D6-A4ZB-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |